Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1054616
Abstract: Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers.… read more here.
Keywords: chlorambucil; cancer; olaparib chlorambucil; treatment cancer ... See more keywords